Propanc Biopharma Seeks Orphan Drug Status for PRP, Its Lead Product for Ovarian Cancer Treatment

Propanc Biopharma Seeks Orphan Drug Status for PRP, Its Lead Product for Ovarian Cancer Treatment
Propanc Biopharma has submitted an orphan drug designation request to the U.S. Food and Drug Administration (FDA) for PRP, its lead product for treatment of ovarian cancer. PRP is an intravenous therapy composed by two pancreatic proenzymes – trypsinogen and chymotrypsinogen. “Obtaining orphan drug designation from the FDA for our PRP therapy for ovarian cancer is

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *